SAN DIEGO, Nov. 05, 2015 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) will hold a conference call to discuss the Company’s financial results through September 30, 2015 and its business outlook. Reggie Groves, the Company’s Chief Executive Officer, will host the call.

The call is scheduled for 2:00 p.m. PST on Wednesday, November 11, 2015 (which is 9:00 a.m. AEDT on Thursday, 12 November 2015) and may be accessed within the United States and Canada by dialing 1-877-312-5413 five minutes prior to the scheduled start time. Callers in Australia may access the call by dialing (02) 8223 9773. If you are asked to provide an access code, please spell out the word “REVA” to the operator and you will be connected promptly.

If you reside outside of the United States, Canada, or Australia, or if you prefer to access the audiocast through our website, please visit “Events & Presentations” under the “Investors” section of our website at www.revamedical.com, and click on the “listen to webcast” link. A replay of the audiocast will be available on our website after the call.

About REVA

REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable stents, which are called “scaffolds” because of their temporary nature. The Company’s scaffolds have been developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s initial product, the Fantom® scaffold, has been designed to offer an ideal balance of thinness and strength and distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize Fantom or any other products.

United States
Investor & Media Enquiries:
REVA Medical, Inc.
Cheryl Liberatore
Director, Communications
+1 858-966-3045

Australia
Investor Enquiries:
Inteq Limited
Kim Jacobs
+61 2 9229 2700

Australia
Media Enquiries:
Buchan Consulting
Rebecca Wilson
+61 3 9866 4722
Annabel Murphy
+61 2 9237 2800

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.